La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

Identifieur interne : 004311 ( Main/Merge ); précédent : 004310; suivant : 004312

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

Auteurs : P. Damier [France] ; E C Hirsch ; Yves Agid [France] ; A M Graybiel

Source :

RBID : pubmed:10430830

English descriptors

Abstract

To achieve accuracy in studying the patterns of loss of midbrain dopamine-containing neurons in Parkinson's disease, we used compartmental patterns of calbindin D(28K) immunostaining to subdivide the substantia nigra with landmarks independent of the degenerative process. Within the substantia nigra pars compacta, we identified dopamine-containing neurons in the calbindin-rich regions ('matrix') and in five calbindin-poor pockets ('nigrosomes') defined by analysis of the three-dimensional networks formed by the calbindin-poor zones. These zones were recognizable in all of the brains, despite severe loss of dopamine-containing neurons. The degree of loss of dopamine-containing neurons in the substantia nigra pars compacta was related to the duration of the disease, and the cell loss followed a strict order. The degree of neuronal loss was significantly higher in the nigrosomes than in the matrix. Depletion was maximum (98%) in the main pocket (nigrosome 1), located in the caudal and mediolateral part of the substantia nigra pars compacta. Progressively less cell loss was detectable in more medial and more rostral nigrosomes, following the stereotyped order of nigrosome 1 > nigrosome 2 > nigrosome 4 > nigrosome 3 > nigrosome 5. A parallel, but lesser, caudorostral gradient of cell loss was observed for dopamine-containing neurons included in the matrix. This pattern of neuronal loss was consistent from one parkinsonian substantia nigra pars compacta to another. The spatiotemporal progression of neuronal loss related to disease duration can thus be drawn in the substantia nigra pars compacta for each Parkinson's disease patient: depletion begins in the main pocket (nigrosome 1) and then spreads to other nigrosomes and the matrix along rostral, medial and dorsal axes of progression.

PubMed: 10430830

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:10430830

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.</title>
<author>
<name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3">
<nlm:affiliation>INSERM U289, Hôpital de la Salpêtrière, Paris, France. cic.salpetriere@psl.ap-hop-paris.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
<author>
<name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name>
<affiliation>
<country>France</country>
<placeName>
<settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
<country>France</country>
<placeName>
<settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
<author>
<name sortKey="Graybiel, A M" sort="Graybiel, A M" uniqKey="Graybiel A" first="A M" last="Graybiel">A M Graybiel</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10430830</idno>
<idno type="pmid">10430830</idno>
<idno type="wicri:Area/PubMed/Corpus">001384</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001384</idno>
<idno type="wicri:Area/PubMed/Curation">001343</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001343</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001343</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001343</idno>
<idno type="wicri:Area/Ncbi/Merge">000044</idno>
<idno type="wicri:Area/Ncbi/Curation">000044</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000044</idno>
<idno type="wicri:doubleKey">0006-8950:1999:Damier P:the:substantia:nigra</idno>
<idno type="wicri:Area/Main/Merge">004311</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.</title>
<author>
<name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name>
<affiliation wicri:level="3">
<nlm:affiliation>INSERM U289, Hôpital de la Salpêtrière, Paris, France. cic.salpetriere@psl.ap-hop-paris.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U289, Hôpital de la Salpêtrière, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hirsch, E C" sort="Hirsch, E C" uniqKey="Hirsch E" first="E C" last="Hirsch">E C Hirsch</name>
</author>
<author>
<name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Yves Agid</name>
<affiliation>
<country>France</country>
<placeName>
<settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
<country>France</country>
<placeName>
<settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
<author>
<name sortKey="Graybiel, A M" sort="Graybiel, A M" uniqKey="Graybiel A" first="A M" last="Graybiel">A M Graybiel</name>
</author>
</analytic>
<series>
<title level="j">Brain : a journal of neurology</title>
<idno type="ISSN">0006-8950</idno>
<imprint>
<date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Calbindins</term>
<term>Dopamine (analysis)</term>
<term>Dopamine (metabolism)</term>
<term>Humans</term>
<term>Nerve Degeneration (pathology)</term>
<term>Nerve Tissue Proteins (analysis)</term>
<term>Neurons (cytology)</term>
<term>Neurons (metabolism)</term>
<term>Neurons (pathology)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (pathology)</term>
<term>Reference Values</term>
<term>S100 Calcium Binding Protein G (analysis)</term>
<term>Substantia Nigra (cytology)</term>
<term>Substantia Nigra (metabolism)</term>
<term>Substantia Nigra (pathology)</term>
<term>Tyrosine 3-Monooxygenase (analysis)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Dopamine</term>
<term>Nerve Tissue Proteins</term>
<term>S100 Calcium Binding Protein G</term>
<term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Calbindins</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Neurons</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Neurons</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Nerve Degeneration</term>
<term>Neurons</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Humans</term>
<term>Reference Values</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">To achieve accuracy in studying the patterns of loss of midbrain dopamine-containing neurons in Parkinson's disease, we used compartmental patterns of calbindin D(28K) immunostaining to subdivide the substantia nigra with landmarks independent of the degenerative process. Within the substantia nigra pars compacta, we identified dopamine-containing neurons in the calbindin-rich regions ('matrix') and in five calbindin-poor pockets ('nigrosomes') defined by analysis of the three-dimensional networks formed by the calbindin-poor zones. These zones were recognizable in all of the brains, despite severe loss of dopamine-containing neurons. The degree of loss of dopamine-containing neurons in the substantia nigra pars compacta was related to the duration of the disease, and the cell loss followed a strict order. The degree of neuronal loss was significantly higher in the nigrosomes than in the matrix. Depletion was maximum (98%) in the main pocket (nigrosome 1), located in the caudal and mediolateral part of the substantia nigra pars compacta. Progressively less cell loss was detectable in more medial and more rostral nigrosomes, following the stereotyped order of nigrosome 1 > nigrosome 2 > nigrosome 4 > nigrosome 3 > nigrosome 5. A parallel, but lesser, caudorostral gradient of cell loss was observed for dopamine-containing neurons included in the matrix. This pattern of neuronal loss was consistent from one parkinsonian substantia nigra pars compacta to another. The spatiotemporal progression of neuronal loss related to disease duration can thus be drawn in the substantia nigra pars compacta for each Parkinson's disease patient: depletion begins in the main pocket (nigrosome 1) and then spreads to other nigrosomes and the matrix along rostral, medial and dorsal axes of progression.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004311 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004311 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:10430830
   |texte=   The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:10430830" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024